Jump to content

Brian King (epidemiologist)

Add links
From Wikipedia, the free encyclopedia
Brian King
Born (1982-09-05) September 5, 1982 (age 42)
Rochester, New York U.S.
EducationUniversity at Buffalo (B.S., MPH, PhD)
OccupationDirector of the Center for Tobacco Products (CTP)
EmployerFood and Drug Administration
Known forTobacco prevention and control
Height5'10
PredecessorMitch Zeller
Websitehttps://www.fda.gov/tobacco-products

Brian King (born 1982) is an American Epidemiologist who currently serves as the Director of the Food and Drug Administration's Center for Tobacco Products (CTP). He was appointed to his role in July 2022.[1]

As the lead tobacco regulatory official for the United States, King is responsible for overseeing the Center's implementation of the Family Smoking Prevention and Tobacco Control Act. Signed into law on June 22, 2009, the Act gives the FDA the authority to regulate the manufacture, distribution, and marketing of tobacco products in the United States.[2]

Prior to joining FDA, he served as the Deputy Director for Research Translation in CDC's Office on Smoking and Health,[3] and more recently as the Executive Editor of CDC's Morbidity & Mortality Weekly Report Series.[4] Prior to his tenure at CDC, he was a Research Affiliate[5] in the Division of Cancer Prevention and Population Sciences at Roswell Park Comprehensive Cancer Center in Buffalo, New York.

He has authored more than 200 scientific journal articles related to tobacco prevention and control.[6] He served as a Senior Editor for multiple U.S. Surgeon General's Reports on tobacco, including “Smoking Cessation: A Report of the Surgeon General” (2020).[7] He was also lead author of CDC's 2014 evidence-based guide for states, “Best Practices for Comprehensive Tobacco Control Programs.[8]”

Early life and education

[edit]

Brian Alexander King was born on September 5, 1982, in Rochester, New York, to Elaine Louise (née Tripi; 1949- 2020) and Geoffrey Walrath King (1946). He is the second of three children born to both parents. His father is a University at Buffalo (SUNY)-educated Optical Physicist who has held various positions in the field with Xerox and at the University of Rochester. King's mother, an alumna of University at Buffalo (SUNY), was a Medical Technologist at Monroe Community Hospital prior to full-time motherhood.[9] He is the third generation of his family to earn a college degree.

King grew up in Webster, New York, a suburb of Rochester. He was an ambitious child interested in science, government, and the creative arts. In high school, he served as Vice President of the school's chapter of the National Honor Society, and as Captain of the Varsity Tennis Team. He is also an accomplished pianist, and performed at numerous community events, including The Great New York State Fair. In 1997, he earned the rank of Eagle Scout with the Boy Scouts of America.[10]

King attended Bishop Kearney High School in Irondequoit, New York (2000). After completing his primary and secondary studies, he was accepted to the University at Buffalo (SUNY) where he earned a Bachelor of Science degree in Biological Sciences with a minor in Music. (2004). King went on to earn Master of Public Health (2006), and Doctor of Philosophy (2010) degrees in Epidemiology at the University at Buffalo (SUNY).[11] His doctoral dissertation advisor was Andrew Hyland, current Chair of the Department of Health Behavior at Roswell Park Comprehensive Cancer Center in Buffalo, New York.

Career

[edit]

Roswell Park Comprehensive Cancer Center

[edit]

In 2005, King was hired as a quitline counselor at the New York State Smokers’ Quitline, which is housed at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Concurrently, he was also working within the organization's Department of Health Behavior to complete the thesis for his Master of Public Health degree at University at Buffalo (SUNY); the thesis was focused on socioeconomic variation in tobacco product advertising across Western New York. In 2006, upon completion of his Master's degree, he was hired as a Research Affiliate within the Department of Health Behavior, Division of Cancer Prevention and Population Sciences, at Roswell Park Comprehensive Cancer Center. The Department was led at the time by Dr. K. Michael Cummings, and King reported directly to Dr. Andrew Hyland. Both had adjunct appointments at State University of New York at Buffalo, which enabled King to work at the Cancer Center concurrently to earning his PhD at the University.[12]

Brian King conducts a press conference to commemorate the 5-year anniversary of the 2003 New York State Clean Indoor Air Act.

During his time at Roswell Park, King led multiple projects, including those related to the observational assessment of tobacco advertising in retail venues, environmental assessments of particulate matter from secondhand smoke in indoor environments, and population-based collection of data on tobacco related issues, including through the New York State Adult Tobacco Survey and the International Tobacco Control Survey. He also initiated seminal research on secondhand smoke exposure in multiunit housing, which was the first of its kind internationally. This included the first study to document secondhand smoke exposure between apartments in a single multiunit housing building using environmental assessments of airborne particulate matter.[13]

While at Roswell Park, King served as Principal Investigator of multiple grants, including a grant from the Flight Attendant Medical Research Institute (FAMRI) to assess secondhand smoke in multiunit housing, and an R36 dissertation grant from the U.S. Centers for Disease Control and Prevention to assess an intervention for enhanced adoption of smoke-free multiunit housing policies.

King first gained media experience during his time at Roswell Park, including serving as the organization's primary spokesperson during a press conference in 2008 to commemorate the 5-year anniversary of the 2003 New York State Clean Indoor Air Act.  

Centers for Disease Control and Prevention (CDC)

[edit]

In July 2010, King joined the Epidemic Intelligence Service (EIS) at CDC. He served as an EIS Officer during 2010-2012, during which he was assigned to the agency's Office on Smoking and Health (OSH) in the National Center for Chronic Disease Prevention and Health Promotion. He led multiple field investigations, including a study[14] of indoor air quality from secondhand smoke in hospitality venues throughout American Samoa, Guam, and the Commonwealth of the Northern Mariana Islands.

Following completion of EIS, he was hired as an Epidemiologist in OSH, and promoted to Senior Scientific Advisor in 2014. In 2015, he assumed the role of Deputy Director for Research Translation in OSH. In this role, King led the agency's efforts related to a variety of high profile matters, including the rise in e-cigarette use among U.S. youth, and the 2014 update to the evidence-based state guide, “Best Practices for Comprehensive Tobacco Control Programs”. He also served a critical role in the development and implementation of the U.S. Department of Housing and Urban Development's 2016 rule[15] that prohibited smoking in public housing nationwide. He is also credited with introducing the “Tobacco Control Vaccine” [16] framework, which was featured on the cover of the scientific journal Tobacco Control in 2018.

Brian King briefs U.S. Surgeon General Vivek Murthy prior to the release of the 2016 Surgeon General's Report on E-Cigarette Use Among Youth and Young Adults.

In his role as Deputy Director for Research Translation in OSH, King was also responsible for leading the U.S. Surgeon General's Reports on tobacco for the U.S. Government under multiple presidential administrations. He served as a reviewer for the 2012 Surgeon General's Report “Preventing Tobacco Use Among Youth and Young Adults”;[17] an author of the 2014 Surgeon General's Report “The Health Consequences of Smoking-50 Years of Progress”;[18] a senior editor of the 2016 Surgeon General's Report “E-cigarette Use Among Youth and Young Adults”;[19] and a senior editor of the 2020 Surgeon General's Report “Smoking Cessation”.[20] He also led the 2018 Surgeon General's Advisory on E-cigarette Use Among Youth.[21]

In March 2022, King was appointed the Executive Editor of CDC's Morbidity & Mortality Weekly Report series.[22]

Brian King conducts a 2014 CDC press briefing on the Tips From Former Smokers Campaign.

During his tenure at CDC, King also served in various leadership capacities for the agency's responses to public health emergencies. He served as senior official for the agency's 2019 response to E-cigarette, or Vaping, Product Use-Associated Lung Injury (EVALI).[23] During 2020-2022, he served in various capacities for the agency's response to Coronavirus Disease 2019 (COVID-19),[24][25] including as Deputy Lead of the Chief Medical Officer Unit, Deputy and then Lead of the Strategic Science Unit, and finally as Chief Science Officer.  

King also served on various inter-agency committees during his tenure at CDC. During 2015-2022, King served as CDC's Ex Officio delegate to FDA's Tobacco Product Scientific Advisory Committee (TPSAC).[26] During 2015-2022, he served as lead for Tobacco Use Objectives for Healthy People 2020 and Health People 2030.

King served as a primary spokesperson on tobacco related issues for CDC during his tenure, and frequently participated in interviews with the news media from major national and international television, radio, and print outlets.[27]

U.S. Food and Drug Administration (FDA)

[edit]

In July 2022, King was appointed the Director of FDA's Center for Tobacco Products (CTP) by FDA Commissioner Dr. Robert Califf.[28] In this role, he serves as the lead tobacco regulatory official for the United States, and is responsible for overseeing the Center's implementation of the Family Smoking Prevention and Tobacco Control Act. Signed into law on June 22, 2009,[2] the Act gives FDA the authority to regulate the manufacture, distribution, and marketing of tobacco products in the United States.

King was the first scientist to be appointed as CTP Director, with his two predecessors being a medical doctor[29] and a lawyer,[30] respectively. King's appointment was applauded by public health organizations and the scientific community,[31] and criticized by some industry organizations, most notably e-cigarette advocacy organizations.[32] He has publicly championed four major areas of prioritization during his tenure as CTP Director, including robust science, stakeholder engagement, effective communication, and health equity.[33]

King assumed the role of CTP Director during a period when FDA was embroiled in multiple high profile controversies, including the agency's decision to issue an administrative stay of its June 2022 marketing denial order to JUUL labs for its e-cigarette products;[34] delays in the agency's review of premarket tobacco product applications, including its newly afforded authority by the U.S. Congress to regulate tobacco products containing synthetic nicotine;[35] criticism over the agency's compliance and enforcement actions, particularly against e-cigarettes; and the resignation of CTP's Office of Science Director, Dr. Matthew Holman, to assume a new role at Philip Morris International, the maker of Marlboro cigarettes.[36] King has publicly referred to his first several months at FDA on several occasions as “baptism by blowtorch”.[37]

During his first year as CTP Director, King led the Center to achieve several actions that were the first of their kind for the agency, including the issuance of the first injunctions,[38] in coordination with the U.S. Department of Justice, filed against manufacturers for the sale of illegal e-cigarette products; the first civil money penalty complaints filed against e-cigarette manufacturers for the sale of illegal e-cigarette products;[39] the agency's first marketing authorization decisions for menthol e-cigarettes, which were marketing denial orders for products by Logic [40] that are presently under appeal by the company; the agency's first warning letters issued to retailers for selling illegal tobacco products since the agency's 2020 deadline for submission of premarket tobacco product applications;[41] and the first judicial seizure of unauthorized e-cigarettes from a distributor in coordination with the U.S. Marshalls Service.[42] In December 2023, King also oversaw the Center's participation in a joint federal operation, in coordination with U.S. Customs and Boarder Protection, that resulted in the seizure of more than $18 million in illegal e-cigarettes at a cargo examination site at Los Angeles International Airport.[43]

Despite these activities, lawmakers remain critical of FDA’s enforcement efforts. On June 12, 2024, King testified to the U.S. Senate Committee to the Judiciary, along with the U.S. Department of Justice.[44] Earlier that week, both agencies announced the creation of a new interagency federal task force to address illicit e-cigarettes.[45]

Director of the Food and Drug Administration's Center for Tobacco Products, Brian King, testifies before the Senate Judiciary Committee during a hearing on Capitol Hill, Wednesday, June 12, 2024, in Washington.

King's tenure has coincided with several high profile efforts to push back on tobacco industry litigation against FDA; this included decisions by the U.S. Solicitor General to appeal a decision by the U.S. Fifth Circuit in RJ Reynolds v. FDA that blocked FDA's rule to require graphic warning labels on cigarette packs in the United States,[46] and to appeal a decision by the U.S. District Court for the District of Columbia in Cigar Association of America v FDA that vacated the agency's ability to regulate premium cigars.[47] In July 2024, at the request of FDA, the U.S. Supreme Court agreed to hear the agency’s defense of its premarket application decisions in FDA v Wages and White Lion. [48]

During his time as CTP Director, the Center has also worked to finalize product standards to prohibit menthol in cigarettes and to prohibit all characterizing flavors in cigars,[49] and has continued to relay its intent to propose a rule to cap the maximum level of nicotine in cigarettes and certain other smoked tobacco products to nonaddictive or minimally addictive levels.[50] Under King's leadership, the agency successfully submitted both the menthol cigarette and flavored cigar products standards to the White House Office of Management and Budget in October 2023, representing the farthest the agency has ever been able to advance the rules after more than a decade of challenges.[51] As of February 2024, both product standards remained on the White House's Unified Agenda; however, their fate remains uncertain given concerns by the White House that they could affect President Biden's reelection prospects.[52]  

Brian King meets with U.S. Senator from Illinois and Senate Majority Whip, Dick Durbin, in 2022 at the U.S. Capitol.

During King's tenure as Director, the Center completed acceptance review of 100% of the 1 million applications received for non-tobacco nicotine (e.g. synthetic nicotine) products following the April 2022 law clarifying FDA's authority to regulate this products.[53] However, the Center continues to receive criticism over its delays in reviewing all premarket tobacco product applications received by the agency by the 2020 deadline, including those court-ordered in American Academy of Pediatrics (AAP) v. FDA.[54] King has publicly stated that the Center has completed review of more than 99% of the 26 million applications received, and is on track to complete review of the remaining AAP-required applications by the end of 2023.[55] The agency has cited litigation and industry-submitted application amendments as reasons for the delay.[56] King has been unapologetically blunt in response to critics of the agency's delay in review of the applications, stating the critiques are coming from the “cheap seats” and that the situation is “a very complex chess match, not a game of tic-tac-toe.”[57]

King has also provided leadership over a high profile update to the Center's programmatic activities. In February 2023, King announced the Center's plans to address the recommendations from an external evaluation by the Reagan-Udall Foundation; this included a new 5-year strategic plan for the Center.[58] The independent evaluation was requested by the FDA Commissioner in July 2022, a few weeks after King's arrival as Center Director.[59] The strategic plan was released on time in December 2023.

Brian King speaks to attendees of the 2nd Global Tobacco Control Policy Forum hosted by the Ministry of Health and Welfare of South Korea in Seoul.

King has been an outspoken champion of health equity. In May 2023, King appointed CTP's first Senior Advisor for Health Equity.[60] He also oversaw the discontinuation of the Center's use of the term “grandfathered” when referring to preexisting tobacco products (i.e. those on the market before 2007, which are excluded from FDA regulation by the Tobacco Control Act) due to the term's historical ties to 19th Century racist voting laws.[61]

In addition to domestic tobacco regulatory activities, King also regularly engages with international tobacco regulatory counterparts. In September 2023, he spoke at the 2nd Global Tobacco Control Policy Forum hosted by the Ministry of Health and Welfare of South Korea in Seoul, Korea.[62] In February 2024, he was part of the U.S. Delegation to the 10th session of the Conference of the Parties to the World Health Organization's Framework Convention on Tobacco Control,[63] which was held in Panama City, Panama.

Notable publications

[edit]
  • Califf RM, King BA. The Need for a Smoking Cessation "Care Package".[64] JAMA. 2023 Jan 17;329(3):203-204. doi: 10.1001/jama.2022.24398. PMID 36580350.
  • King BA. Flavors Are a Major Driver of the Youth E-Cigarette Epidemic. Am J Public Health. 2020 Jun;110(6):773-774. doi: 10.2105/AJPH.2020.305670. Erratum in: Am J Public Health. 2021 Feb;111(2):e6. PMID 32374696; PMCID: PMC7204467.
  • Kirkcaldy RD, King BA, Brooks JT. COVID-19 and Postinfection Immunity: Limited Evidence, Many Remaining Questions. JAMA. 2020 Jun 9;323(22):2245-2246. doi: 10.1001/jama.2020.7869. PMID 32391855; PMCID: PMC8596300.
  • King BA, Jones CM, Baldwin GT, Briss PA. The EVALI and Youth Vaping Epidemics - Implications for Public Health. N Engl J Med. 2020 Feb 20;382(8):689-691. doi: 10.1056/NEJMp1916171. Epub 2020 Jan 17. PMID 31951683; PMCID: PMC7122126.
  • King BA, Gammon DG, Marynak KL, Rogers T. Electronic Cigarette Sales in the United States, 2013-2017. JAMA. 2018 Oct 2;320(13):1379-1380. doi: 10.1001/jama.2018.10488. PMID 30285167; PMCID: PMC6233837.
  • King BA, Graffunder C. The Tobacco Control Vaccine: a population-based framework for preventing tobacco-related disease and death. Tob Control. 2018 Mar;27(2):123-124. doi: 10.1136/tobaccocontrol-2018-054276. PMID 29475955; PMCID: PMC5850888.
  • King BA, Creamer MR, Harrell M, Kelder S, Norman L, Perry CL. Surgeon General's Reports on Tobacco: A Continued Legacy of Unbiased and Rigorous Synthesis of the Scientific Evidence. Nicotine Tob Res. 2018 Jul 9;20(8):1033-1036. doi: 10.1093/ntr/ntx266. PMID 29300946; PMCID: PMC6023778.
  • King BA, Peck RM, Babb SD. Cost savings associated with prohibiting smoking in U.S. subsidized housing. Am J Prev Med. 2013 Jun;44(6):631-4. doi: 10.1016/j.amepre.2013.01.024. PMID 23683981; PMCID: PMC4572888.
  • King BA, Dube SR, Tynan MA. Current tobacco use among adults in the United States: findings from the National Adult Tobacco Survey. Am J Public Health. 2012 Nov;102(11):e93-e100. doi: 10.2105/AJPH.2012.301002. Epub 2012 Sep 20. PMID 22994278; PMCID: PMC3477973.
  • King BA, Travers MJ, Cummings KM, Mahoney MC, Hyland AJ. Secondhand smoke transfer in multiunit housing. Nicotine Tob Res. 2010 Nov;12(11):1133-41. doi: 10.1093/ntr/ntq162. Epub 2010 Oct 1. PMID 20889473; PMCID: PMC3436457.

Awards and honors

[edit]
  • 2020: Charles C. Shepard Award, Excellence in Assessment, U.S. Centers for Disease Control and Prevention[65]
  • 2016: George W. Thorn Award, UB Alumni Association, Status University of New York at Buffalo[66]
  • 2014: Alumni Inductee, Delta Omega Public Health Honor Society, Gamma Lambda Chapter, State University of New York at Buffalo[67]
  • 2010: Saxon Graham Award, School of Public Health and Health Related Professions, State University of New York at Buffalo[68]

References

[edit]
  1. ^ Products, Center for Tobacco (2023-05-24). "Brian King". U.S. Food and Drug Administration. Retrieved 2023-06-14.
  2. ^ a b Products, Center for Tobacco (2022-10-04). "Family Smoking Prevention and Tobacco Control Act - An Overview". FDA.
  3. ^ "Course Summary". tceols.cdc.gov. Retrieved 2023-06-17.
  4. ^ "AACR Applauds the Appointment of Brian A. King, PhD, MPH, as Director of the FDA Center for Tobacco Products". American Association for Cancer Research (AACR). Retrieved 2023-06-25.
  5. ^ "Secondhand Smoke Poses Hazards To Apartment Residents". Roswell Park Comprehensive Cancer Center. 2010-10-18. Retrieved 2023-06-17.
  6. ^ "King BA - Search Results - PubMed". PubMed. Retrieved 2023-06-17.
  7. ^ General, United States Public Health Service Office of the Surgeon; Health, National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and (2020), "Acknowledgments", Smoking Cessation: A Report of the Surgeon General [Internet], US Department of Health and Human Services, retrieved 2023-06-17
  8. ^ "Best Practices for Comprehensive Tobacco Control Programs—2014". Centers for Disease Control and Prevention. 2023-02-06. Retrieved 2023-06-17.
  9. ^ "Obituary of Elaine L. King | Willard H. Scott Funeral Home Inc". willardhscott.com. Retrieved 2023-06-27.
  10. ^ "Awards and Recognition". The National Eagle Scout Association. Retrieved 2023-06-26.
  11. ^ ""There is a strong history of collaborative, interdisciplinary and innovative research here, and I'm proud to have been a part of it."". publichealth.buffalo.edu. Retrieved 2023-06-26.
  12. ^ ""There is a strong history of collaborative, interdisciplinary and innovative research here, and I'm proud to have been a part of it."". publichealth.buffalo.edu. Retrieved 2023-06-18.
  13. ^ King, B. A.; Travers, M. J.; Cummings, K. M.; Mahoney, M. C.; Hyland, A. J. (2010-11-01). "Secondhand Smoke Transfer in Multiunit Housing". Nicotine & Tobacco Research. 12 (11): 1133–1141. doi:10.1093/ntr/ntq162. ISSN 1462-2203. PMC 3436457. PMID 20889473.
  14. ^ King, B. A.; Dube, S. R.; Ko, J. Y. (2011). "King BA, Dube SR, Ko JY. Secondhand smoke concentrations in hospitality venues in the Pacific Basin: findings from American Samoa, Commonwealth of the Northern Mariana Islands, and Guam". Asian Pacific Journal of Cancer Prevention. 12 (11): 2881–2885. PMC 4583773. PMID 22393958.
  15. ^ "Smoke-Free Public Housing". HUD.gov / U.S. Department of Housing and Urban Development (HUD). Retrieved 2023-06-25.
  16. ^ King, Brian A.; Graffunder, Corinne (March 27, 2018). "The Tobacco Control Vaccine: a population-based framework for preventing tobacco-related disease and death". Tobacco Control. 27 (2): 123–124. doi:10.1136/tobaccocontrol-2018-054276. ISSN 1468-3318. PMC 5850888. PMID 29475955.
  17. ^ "2012 Surgeon General's Report | Smoking & Tobacco Use | CDC". www.cdc.gov. 2022-05-03. Retrieved 2023-06-25.
  18. ^ "2014 SGR: The Health Consequences of Smoking—50 Years of Progress". Centers for Disease Control and Prevention. 2021-06-02. Retrieved 2023-06-25.
  19. ^ "2016 SGR: E-Cigarette Use Among Youth and Young Adults". Centers for Disease Control and Prevention. 2017-07-24. Retrieved 2023-06-25.
  20. ^ "2020 SGR: Smoking Cessation". Centers for Disease Control and Prevention. 2022-06-07. Retrieved 2023-06-25.
  21. ^ "Surgeon General's Advisory on E-cigarette Use Among Youth | Smoking & Tobacco Use | CDC". www.cdc.gov. 2022-12-05. Retrieved 2023-06-25.
  22. ^ Products, Center for Tobacco (2023-05-24). "Brian King". U.S. Food and Drug Administration. Retrieved 2023-06-25.
  23. ^ King, Brian A.; Jones, Christopher M.; Baldwin, Grant T.; Briss, Peter A. (2020-02-20). "The EVALI and Youth Vaping Epidemics — Implications for Public Health". New England Journal of Medicine. 382 (8): 689–691. doi:10.1056/NEJMp1916171. ISSN 0028-4793. PMC 7122126. PMID 31951683.
  24. ^ Kirkcaldy, Robert D.; King, Brian A.; Brooks, John T. (2020-06-09). "COVID-19 and Postinfection Immunity: Limited Evidence, Many Remaining Questions". JAMA. 323 (22): 2245–2246. doi:10.1001/jama.2020.7869. ISSN 0098-7484. PMC 8596300. PMID 32391855.
  25. ^ Meites, Elissa; Knuth, Martha; Hall, Kaely; Dawson, Patrick; Wang, Teresa W.; Wright, Marcienne; Yu, Wei; Senesie, Schabbethai; Stephenson, Elizabeth; Imachukwu, Chukwuebuka; Sayi, Takudzwa; Gurbaxani, Brian; Svendsen, Erik R.; Khoury, Muin J.; Ellis, Barbara (2023). "COVID-19 Scientific Publications From the Centers for Disease Control and Prevention, January 2020-January 2022". Public Health Reports (Washington, D.C.: 1974). 138 (2): 241–247. doi:10.1177/00333549221134130. ISSN 1468-2877. PMC 9692168. PMID 36416100.
  26. ^ Products, Center for Tobacco (2023-03-10). "Past Meeting Materials: Tobacco Products Scientific Advisory Committee". FDA.
  27. ^ "CDC Newsroom". CDC. 2016-01-01. Retrieved 2023-06-18.
  28. ^ "After a robust executive search". Twitter. May 20, 2022. Retrieved 2023-06-18.
  29. ^ Gottlieb, Scott. "More Personnel Changes at FDA". Forbes. Retrieved 2023-06-18.
  30. ^ "Read Mitch Zeller's Reflections on His Experiences as CTP Director". U.S. Food and Drug Administration. Retrieved 2023-06-18.
  31. ^ "AACR Applauds the Appointment of Brian A. King, PhD, MPH, as Director of the FDA Center for Tobacco Products". American Association for Cancer Research (AACR). Retrieved 2023-06-18.
  32. ^ "With No Regulatory Experience, Brian King Will Be CTP Director". Vaping360. 23 May 2022. Retrieved 2023-06-18.
  33. ^ "Future Priorities for Federal Commercial Tobacco Regulation: A Conversation with Dr. Brian King | Public Health Law Center". www.publichealthlawcenter.org. Retrieved 2023-06-18.
  34. ^ Commissioner, Office of the (2022-07-05). "FDA Denies Authorization to Market JUUL Products". FDA. Retrieved 2023-06-18.
  35. ^ "FDA decision to delay ruling on tobacco applications for market leaders 'deeply disappointing'". American Heart Association. Retrieved 2023-06-18.
  36. ^ Jewett, Christina (2022-07-27). "F.D.A. Tobacco Science Official Takes Job at Philip Morris". The New York Times. ISSN 0362-4331. Retrieved 2023-06-18.
  37. ^ Foley, Katherine Ellen; Lim, David (2023-05-19). "A positive sign for RSV protection for infants". POLITICO. Retrieved 2023-06-25.
  38. ^ Commissioner, Office of the (2022-10-24). "FDA, DOJ Seek Permanent Injunctions Against Six E-cigarette Manufacturers". FDA. Retrieved 2023-06-25.
  39. ^ Commissioner, Office of the (2023-02-22). "FDA Files Civil Money Penalty Complaints Against Four E-Cigarette Product Manufacturers". FDA. Retrieved 2023-06-18.
  40. ^ Commissioner, Office of the (2023-01-10). "FDA Denies Marketing of Logic's Menthol E-Cigarette Products Following Determination They Do Not Meet Public Health Standard". FDA. Retrieved 2023-06-25.
  41. ^ Commissioner, Office of the (2023-06-01). "FDA Conducts Retailer Inspection Blitz, Cracks Down on Illegal Sales of Popular Disposable E-cigarettes". FDA. Retrieved 2023-06-18.
  42. ^ Products, Center for Tobacco (2024-05-01). "FDA, DOJ Seize Over $700,000 Worth of Unauthorized E-Cigarettes". FDA.
  43. ^ Commissioner, Office of the (2023-12-14). "Joint Federal Operation Results in Seizure of More Than $18 Million in Illegal E-Cigarettes". FDA. Retrieved 2024-02-26.
  44. ^ "Combatting the Youth Vaping Epidemic by Enhancing Enforcement Against Illegal E-Cigarettes | United States Senate Committee on the Judiciary". www.judiciary.senate.gov. Retrieved 2024-08-05.
  45. ^ Commissioner, Office of the (2024-06-13). "Justice Department and FDA Announce Federal Multi-Agency Task Force to Curb the Distribution and Sale of Illegal E-Cigarettes". FDA. Retrieved 2024-08-05.
  46. ^ "R.J. Reynolds v. FDA (2020) | The tobacco industry filed suit on First Amendment grounds to challenge the FDA's graphic warning label rule". www.publichealthlawcenter.org. Retrieved 2024-02-26.
  47. ^ "FDA Appeals Judge's Decision Tossing Premium Cigars Regulation". news.bloomberglaw.com. Retrieved 2024-02-26.
  48. ^ "Search - Supreme Court of the United States". www.supremecourt.gov. Retrieved 2024-08-05.
  49. ^ Commissioner, Office of the (2022-05-06). "Tobacco Product Standard for Characterizing Flavors in Cigars (Proposed Rule) Preliminary Regulatory Impact Analysis". FDA.
  50. ^ Commissioner, Office of the (2022-06-24). "FDA Announces Plans for Proposed Rule to Reduce Addictiveness of Cigarettes and Other Combusted Tobacco Products". FDA. Retrieved 2023-06-18.
  51. ^ Products, Center for Tobacco (2024-02-22). "A Year in Review: FDA's Progress on Tobacco Product Regulation in 2023". FDA.
  52. ^ "A top official fears Biden might let politics interfere with public health". POLITICO. 2024-02-15. Retrieved 2024-02-26.
  53. ^ Products, Center for Tobacco (2023-03-15). "FDA Makes Determinations On More Than 99% of the 26 Million Tobacco Products For Which Applications Were Submitted". FDA.
  54. ^ "Consolidated in 4th Circuit with: In re: American E-Liquid, Docket No. 19-02242 (4th Cir. Nov 06, 2019); American Academy of Pediatrics v. American E-Liquid, Docket No. 19-02132 (4th) Cir. Oct 16, 2019); and In re: Cigar Association, Docket No. 19-02130 (4th Cir. Oct 16, 2019)". Public Health Law Center. March 27, 2018. Retrieved June 25, 2023.
  55. ^ Products, Center for Tobacco (2023-02-24). "Perspective: Update on FDA Review and Enforcement of Non-Tobacco Nicotine Products". FDA.
  56. ^ Products, Center for Tobacco (2024-02-22). "A Year in Review: FDA's Progress on Tobacco Product Regulation in 2023". FDA.
  57. ^ Jewett, Christina (2023-10-10). "Illicit E-Cigarettes Flood Stores as F.D.A. Struggles to Combat Imports". The New York Times. ISSN 0362-4331. Retrieved 2024-02-26.
  58. ^ Products, Center for Tobacco (2023-02-24). "An All-Center Approach: CTP's Response to the Reagan-Udall Foundation Evaluation Report". FDA.
  59. ^ Commissioner, Office of the (2022-07-19). "FDA Conducting Evaluation of Key Agency Activities to Strengthen Operations". FDA. Retrieved 2023-07-01.
  60. ^ Products, Center for Tobacco (2023-05-22). "CTP Hires Its First Senior Advisor for Health Equity". FDA.
  61. ^ Products, Center for Tobacco (2022-10-28). "CTP Updates "Grandfathered Tobacco Product" Term to "Pre-Existing Tobacco Product"". FDA.
  62. ^ Commissioner, Office of the (2023-10-12). "Public Calendar: September 17-23, 2023". FDA.
  63. ^ "FDA Global on X". Twitter. February 5, 2024. Retrieved February 25, 2024.
  64. ^ Califf, Robert M.; King, Brian A. (2023-01-17). "The Need for a Smoking Cessation "Care Package"". JAMA. 329 (3): 203–204. doi:10.1001/jama.2022.24398. ISSN 1538-3598. PMID 36580350. S2CID 255292817.
  65. ^ "CDC - 2020 Charles C. Shepard Science Awards". www.cdc.gov. 2023-03-23. Retrieved 2023-06-17.
  66. ^ "Past Award Recipients". www.buffalo.edu. Retrieved 2023-06-17.
  67. ^ "Delta Omega Honorary Society Gamma Lambda Chapter". publichealth.buffalo.edu. Retrieved 2023-06-17.
  68. ^ "2023: Brian King, PhD '10, MPH '06". publichealth.buffalo.edu. Retrieved 2023-06-17.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Brian_King_(epidemiologist)&oldid=1250236245"